Volume 71, Issue 1, Pages 55-65 (January 2017) Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications  Boris Gershman, Holly K. Van Houten, Jeph Herrin, Daniel M. Moreira, Simon P. Kim, Nilay D. Shah, R. Jeffrey Karnes  European Urology  Volume 71, Issue 1, Pages 55-65 (January 2017) DOI: 10.1016/j.eururo.2016.03.015 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Interrupted time series analysis of monthly rates of prostate biopsy and 30-d complications (January 2005 to September 2014) among men aged ≥40 yr (n=5279315). AUA=American Urological Association; ERSPC=European Randomized Study of Screening for Prostate Cancer; PLCO=Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; USPSTF=US Preventive Services Task Force. European Urology 2017 71, 55-65DOI: (10.1016/j.eururo.2016.03.015) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 2 Interrupted time series analysis of monthly rates of 30-d postbiopsy complications (January 2005 to September 2014) among men aged ≥40 yr undergoing biopsy (n=104584). AUA=American Urological Association; ERSPC=European Randomized Study of Screening for Prostate Cancer; PLCO=Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; USPSTF=US Preventive Services Task Force. European Urology 2017 71, 55-65DOI: (10.1016/j.eururo.2016.03.015) Copyright © 2016 European Association of Urology Terms and Conditions